Millennium and Wyeth Extend Central Nervous System Collaboration

CAMBRIDGE, Mass.--Millennium Pharmaceuticals announced that its collaboration with Wyeth-Ayerst Research in the area of central nervous system disorders will be extended for at least two more years. Millennium also revealed that it has provided Wyeth with a third novel candidate gene, the discovery of which activates an undisclosed milestone payment to Millennium. Under the original 1996 agreement, Wyeth agreed to pay Millennium up to $90 million in licensing fees and research payments to access genomic technologies and fund research, including human population genetic studies, aimed at developing novel treatments for a broad range of CNS diseases.